Claus Schalper
Vorstandsvorsitzender bei XL-protein GmbH
Ursprung des Netzwerks ersten Grades von Claus Schalper
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
Isarna Therapeutics GmbH
 Isarna Therapeutics GmbH BiotechnologyHealth Technology Isarna Therapeutics GmbH engages in developing selective TGF-ß inhibitors. It works on a pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcome. The company focuses on biopharmaceutical research, pipeline development, and partnering and licensing programs. Isarna Therapeutics was founded by Karl-Hermann Schlingensiepen and Reimar Schlingensiepen in 1998 and is headquartered in Munich, Germany.
2
| Holding Company | Biotechnology | 2 |
Anavo Therapeutics BV
 Anavo Therapeutics BV BiotechnologyHealth Technology Anavo Therapeutics BV is a Dutch company that specializes in developing first-in-class therapeutic programs for several indications in oncology. The company is based in Leiden, Netherlands. The company has attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. Anavo is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades. Anavo is backed by blue-chip investors m ventures, inkef capital, taiho ventures, mrl ventures fund, and bioqube ventures. The company was founded by Claus Schalper, Birgit Zech, Gerhard Müller. Birgit Zech has been the CEO since incorporation.
2
| Holding Company | Biotechnology | 2 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Claus Schalper
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
Agouron Pharmaceuticals LLC
 Agouron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Agouron Pharmaceuticals LLC develops and distributes therapeutic products. It provides therapeutic products which are used in the treatment of cardiovascular disease, central nervous system diseases and disorders, neurological disorders, inflammatory diseases, respiratory diseases, infectious diseases, immunological disorders, pharmaceutical preparations and other diseases. The company was founded in 1984 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| ALLERGAN, INC. | Pharmaceuticals: Major | Director/Board Member | |
| Warwick Business School | College/University | Masters Business Admin | |
| KALA BIO, INC. | Pharmaceuticals: Major | President | |
| University of California, Santa Barbara | College/University | Graduate Degree | |
| University of California, Santa Cruz | College/University | Undergraduate Degree | |
| University of San Diego | College/University | Masters Business Admin | |
| Friedrich-Alexander University of Erlangen-Nuremberg | College/University | Doctorate Degree | |
| Charité - Universitätsmedizin Berlin | College/University | Doctorate Degree | |
Impact Biomedicines, Inc.
 Impact Biomedicines, Inc. Medical SpecialtiesHealth Technology Impact Biomedicines, Inc. engages in the development of cancer treatments. It engages in the development of fedratinib, a potent and selective oral molecule JAK2 kinase inhibitor for the treatment of myelofibrosis and polycythemia vera. The company was founded by John Hood, Catriona Jamieson and Raghu Saripalli in 2016 and is headquartered in San Diego, CA. | Medical Specialties | President | |
Primmune Therapeutics, Inc.
 Primmune Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Primmune Therapeutics, Inc. develops small molecules, orally administered toll-like receptor for cancer immunotherapy and tumors. The firm offers treatment and prevention of viral infections. The company was founded by Paulo Rangel, James Appleman, and Stephen Webber in October, 2017 and is headquartered in San Diego, CA. | Miscellaneous Commercial Services | Chief Executive Officer | |
| EQUILLIUM, INC. | Biotechnology | Director/Board Member | |
Gotham Therapeutics Corp.
 Gotham Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Gotham Therapeutics Corp. develops and manufactures pharmaceutical medicines. The firm develops new treatment options for patients suffering from cancers, auto-immune and neurodegenerative diseases. The company was founded by Samie Jaffrey in 2017 and is headquartered in New York, NY. | Pharmaceuticals: Major | Founder |
Statistik
International
| Vereinigte Staaten | 11 |
| Deutschland | 5 |
| Island | 2 |
| Vereinigtes Königreich | 2 |
Sektoral
| Health Technology | 9 |
| Consumer Services | 7 |
| Commercial Services | 3 |
Operativ
| Corporate Officer/Principal | 6 |
| Chief Executive Officer | 3 |
| President | 3 |
| Director/Board Member | 3 |
| Doctorate Degree | 2 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Charles McDermott | 11 |
| Birgit Zech | 5 |
| René Rückert | 3 |
| Chris Huiskamp | 1 |
- Börse
- Insiders
- Claus Schalper
- Unternehmensverbindungen
